Oxis Intl Inc (OXIS) 0.0165 $OXIS
Oxis International, Inc. Announces Appointment of Michael S. Sitrick to Business Advisory Board
PR Newswire - Mon Oct 05, 7:00AM CDT
Oxis International, Inc. [OTC: OXIS] [Euronext Paris: OXI.PA] announced today that Michael S. Sitrick has joined its Business Advisory Board. Oxis is in the process of building a world class Business Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech Inc. Announces Appointment of Randolph C Read to Business Advisory Board
PR Newswire - Thu Sep 24, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today, Randolph C Read has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech, Inc. Announces Appointment of James L. Nelson to Board
PR Newswire - Tue Sep 15, 7:01AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA], announced today that James L. Nelson has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
HLF: 54.93 (-0.72), VLTC: 6.92 (-0.02)
DUE DILIGENCE REPORT: Four Players are Examined in a Large and Rapidly Growing Market
ACCESSWIRE - Mon Sep 14, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / September 14, 2015 / According to Arc View Market Research, the market for legal marijuana reached $2.7 billion in sales for 2014, growing from $1.53 billion in 2013. This growth is expected to continue, with the market increasing by 32% in 2015, and reaching $10.2 billion by 2018. Between 2009 and 2014, the cannabis industry grew 16.2% annually, and growth is expected to increase to 23.3% annually between 2014 and 2019. Cannabis is currently the fastest growing industry in the United States. If marijuana is legalized at the federal level, revenues for the legal cannabis industry could reach $35 billion by 2020 according to Greenwave Advisors. Currently, 23 states have legalized medical marijuana, and two states, Washington and Colorado, have legalized marijuana for recreational use.
Oxis Biotech to present at the Rodman Renshaw Global Investment Conference
PR Newswire - Wed Sep 09, 6:56AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.
OXIS Biotech, Inc. Licenses Worldwide Rights to Cancer Therapy with Positive FDA Phase I Study Results
ACCESSWIRE - Tue Sep 08, 8:24AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 8, 2015 / Oxis Biotech, a wholly-owned subsidiary of Oxis International, Inc. (OTCQB: OXIS) is a biotech company that we introduced to you back in January 2015 that gained approximately 250% just 3 months after we initiated coverage on the company. This emerging biotech, led by an experienced CEO who once before took an OTC listed biotech with a market cap of about $2M to a NASDAQ main listed company now sporting a $325M market cap, has just released potentially game-changing news.
Oxis Biotech Licenses Exclusive Worldwide Rights To Novel Cancer Therapy
PR Newswire - Tue Sep 08, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. (OTC: OXIS) and (Euronext Paris: OXI.PA) announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.
Analyst Coverage Initiated on Oxis International, Inc. (OXIS) with Speculative Buy Rating Following Recent Corporate Announcements
ACCESSWIRE - Wed Aug 12, 9:48AM CDT
MIAMI, FL / ACCESSWIRE / August 12, 2015 / The immunotherapy market, the market of treatments that use your body's own immune system to help fight cancer, is positioned for exponential growth in the next 5-10 years. It stood at $1.1 billion in 2012 and is expected to grow to at least $9 billion by 2022. That yields a 15.08% expected CAGR for the immunotherapy market, giving one of the highest expected growth rates of any market over the next 5-10 years.
Oxis Biotech Inc. Scientific Advisory Board Member, Dr. James J. Mule, Named as a Master of Immunology by the American Association for Cancer Research
PR Newswire - Tue Aug 11, 7:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS], is pleased to announce that Dr. James J. Mule, member of the Company's Scientific Advisory Board and Associate Center Director for Translational Science at the Moffitt Cancer Center, has been named a Master of Immunology by the American Association for Cancer Research (AACR) publication.
Oxis International, Inc. - "Oxis' Technology is Lightning in a Bottle"
ACCESSWIRE - Mon Jul 27, 7:41AM CDT
NEW YORK, NY / ACCESSWIRE / July 27, 2015 / Oxis International, Inc. (OXIS) (OXI.PA) through its wholly owned subsidiary Oxis Biotech, Inc., today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, Anthony Cataldo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Oxis Biotech Inc. Announces Appointment of Dr. Stephen M. Chang to Scientific Advisory Board
Marketwired - Thu Jun 18, 8:37AM CDT
Oxis International, Inc. (OTCQB: OXIS), a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Dr. Stephen M. Chang has joined the Scientific Advisory Board for its wholly owned subsidiary, Oxis Biotech, Inc.
Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions
PR Newswire - Thu Jun 04, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today it has filed a U.S. patent application covering additional analogs of the company's lead compound, OXS-4235, a potent p62/Sequestosome 1 (p62) inhibitor. These novel p62 inhibitors demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells. Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.
Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
Marketwired - Wed Jun 03, 11:30AM CDT
Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.
Cannabis Stocks On The Rise In 2015
ACCESSWIRE - Thu May 14, 10:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 14, 2015 / Cannabis stocks have rallied in 2015 thus far. With more and more states jumping on board the marijuana legalization train, companies are now trying to take advantage of this rapidly growing space. For instance, companies that are biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), security surveillance for dispensaries like Blue Line Protection Group (PINKSHEETS: BLPG), or hemp infused Beverage Companies like Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have found their place in the MJ space in 2015.
OXIS Biotech Retains The Emmes Group To Assist With Its Strategic Business And Therapeutic Development Initiatives
PR Newswire - Tue May 12, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today that it has retained the Emmes Group to assist with the development and execution of the Company's business, partnership, and technology licensing initiatives and strategies.
How High Have Cannabis Stocks Been This Year And Where Do You Stand?
ACCESSWIRE - Fri May 08, 11:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 8, 2015 / Interest in cannabis companies has continued to grow in 2015 as more states have begun to implement legalization efforts; these including options for both medical and recreational use. After more states like Texas have put wheels in motion for legalization efforts, more attention has begun to build and the 2015 market for cannabis stocks has started to look much different than the uncertainty that was seen last year. Companies like Oxis International (OTCQB: OXIS), Pazoo, Inc. (PINKSHEETS: PZOO), and Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have all seen record 6-month highs this year as a flood of positive news and a more informed investment community have bolstered movement within the market.
The "Tech" Behind Biotechnology Has Evolved; 2015 Marks New Milestones
ACCESSWIRE - Thu May 07, 10:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.
PTBI: 6.61 (+0.08)
Will These Cannabis Stocks Be On Your Watchlist For May?
ACCESSWIRE - Tue May 05, 1:14PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 5, 2015 / Marijuana stocks have made a serious comeback since the start of the New Year. With the hit taken by cannabis companies in 2014 it has attracted investors to invest in oversold cannabis plays. Now it's 2015 and with 23 states including the District of Columbia jumping on the marijuana legislation train, companies are finding new innovative ways to become part of the cannabis industry. For example, biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), Hemp infused beverage wholesalers like Totally Hemp Crazy Inc. (PINKSHEETS: THCZ) and even extensive security & protection services like Blue Line Protection Group (PINKSHEETS: BLPG) have all found their niche in the industry.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part VIII
Anthony Cataldo - at Seeking Alpha - Mon Apr 20, 7:25AM CDT
QAI: 29.10 (+0.04)
Oxis International, Inc. Announces Appointment of Michael S. Sitrick to Business Advisory Board
PR Newswire - Mon Oct 05, 7:00AM CDT
Oxis International, Inc. [OTC: OXIS] [Euronext Paris: OXI.PA] announced today that Michael S. Sitrick has joined its Business Advisory Board. Oxis is in the process of building a world class Business Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech Inc. Announces Appointment of Randolph C Read to Business Advisory Board
PR Newswire - Thu Sep 24, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today, Randolph C Read has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
Oxis Biotech, Inc. Announces Appointment of James L. Nelson to Board
PR Newswire - Tue Sep 15, 7:01AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA], announced today that James L. Nelson has joined its Business Advisory Board. Oxis is in the process of building a world class Advisory Board to assist management in strategy, development and execution. The Business Advisory Board members will become members of the Oxis Board of Directors upon a successful up-listing to the NASDAQ exchange.
HLF: 54.93 (-0.72), VLTC: 6.92 (-0.02)
DUE DILIGENCE REPORT: Four Players are Examined in a Large and Rapidly Growing Market
ACCESSWIRE - Mon Sep 14, 7:35AM CDT
NEW YORK, NY / ACCESSWIRE / September 14, 2015 / According to Arc View Market Research, the market for legal marijuana reached $2.7 billion in sales for 2014, growing from $1.53 billion in 2013. This growth is expected to continue, with the market increasing by 32% in 2015, and reaching $10.2 billion by 2018. Between 2009 and 2014, the cannabis industry grew 16.2% annually, and growth is expected to increase to 23.3% annually between 2014 and 2019. Cannabis is currently the fastest growing industry in the United States. If marijuana is legalized at the federal level, revenues for the legal cannabis industry could reach $35 billion by 2020 according to Greenwave Advisors. Currently, 23 states have legalized medical marijuana, and two states, Washington and Colorado, have legalized marijuana for recreational use.
Oxis Biotech to present at the Rodman Renshaw Global Investment Conference
PR Newswire - Wed Sep 09, 6:56AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] and [Euronext Paris: OXI.PA] announced today the company will be presenting at the 2015 Rodman & Renshaw Global Investment Conference in New York City.
OXIS Biotech, Inc. Licenses Worldwide Rights to Cancer Therapy with Positive FDA Phase I Study Results
ACCESSWIRE - Tue Sep 08, 8:24AM CDT
CORAL GABLES, FL / ACCESSWIRE / September 8, 2015 / Oxis Biotech, a wholly-owned subsidiary of Oxis International, Inc. (OTCQB: OXIS) is a biotech company that we introduced to you back in January 2015 that gained approximately 250% just 3 months after we initiated coverage on the company. This emerging biotech, led by an experienced CEO who once before took an OTC listed biotech with a market cap of about $2M to a NASDAQ main listed company now sporting a $325M market cap, has just released potentially game-changing news.
Oxis Biotech Licenses Exclusive Worldwide Rights To Novel Cancer Therapy
PR Newswire - Tue Sep 08, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. (OTC: OXIS) and (Euronext Paris: OXI.PA) announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.
Analyst Coverage Initiated on Oxis International, Inc. (OXIS) with Speculative Buy Rating Following Recent Corporate Announcements
ACCESSWIRE - Wed Aug 12, 9:48AM CDT
MIAMI, FL / ACCESSWIRE / August 12, 2015 / The immunotherapy market, the market of treatments that use your body's own immune system to help fight cancer, is positioned for exponential growth in the next 5-10 years. It stood at $1.1 billion in 2012 and is expected to grow to at least $9 billion by 2022. That yields a 15.08% expected CAGR for the immunotherapy market, giving one of the highest expected growth rates of any market over the next 5-10 years.
Oxis Biotech Inc. Scientific Advisory Board Member, Dr. James J. Mule, Named as a Master of Immunology by the American Association for Cancer Research
PR Newswire - Tue Aug 11, 7:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS], is pleased to announce that Dr. James J. Mule, member of the Company's Scientific Advisory Board and Associate Center Director for Translational Science at the Moffitt Cancer Center, has been named a Master of Immunology by the American Association for Cancer Research (AACR) publication.
Oxis International, Inc. - "Oxis' Technology is Lightning in a Bottle"
ACCESSWIRE - Mon Jul 27, 7:41AM CDT
NEW YORK, NY / ACCESSWIRE / July 27, 2015 / Oxis International, Inc. (OXIS) (OXI.PA) through its wholly owned subsidiary Oxis Biotech, Inc., today published a new blog post on The Chairman's Blog, written by the Company's Chairman and Chief Executive Officer, Anthony Cataldo. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.
Oxis Biotech Inc. Announces Appointment of Dr. Stephen M. Chang to Scientific Advisory Board
Marketwired - Thu Jun 18, 8:37AM CDT
Oxis International, Inc. (OTCQB: OXIS), a biotechnology company focused on cannabinoid therapy development and commercialization, announced today Dr. Stephen M. Chang has joined the Scientific Advisory Board for its wholly owned subsidiary, Oxis Biotech, Inc.
Oxis Biotech Files U.S. Patent Application Covering p62/Sequestosome 1 Inhibitors For The Treatment Of Multiple Myeloma And Secondary Osteolytic Lesions
PR Newswire - Thu Jun 04, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today it has filed a U.S. patent application covering additional analogs of the company's lead compound, OXS-4235, a potent p62/Sequestosome 1 (p62) inhibitor. These novel p62 inhibitors demonstrate inhibition of multiple myeloma cell growth without toxicity to normal bone marrow stromal cells. Bone marrow stromal cells are involved in hematopoiesis and certain inflammatory processes.
Millennium Healthcare Inc. Appoints Anthony Cataldo, CEO of Oxis Biotech, to Board of Advisors
Marketwired - Wed Jun 03, 11:30AM CDT
Millennium Healthcare Inc. (OTCQB: MHCC), a healthcare services and medical device distribution company, today announced that the Company has appointed Anthony (Tony) Cataldo to the Board of Advisors effective June 1, 2015.
Cannabis Stocks On The Rise In 2015
ACCESSWIRE - Thu May 14, 10:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 14, 2015 / Cannabis stocks have rallied in 2015 thus far. With more and more states jumping on board the marijuana legalization train, companies are now trying to take advantage of this rapidly growing space. For instance, companies that are biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), security surveillance for dispensaries like Blue Line Protection Group (PINKSHEETS: BLPG), or hemp infused Beverage Companies like Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have found their place in the MJ space in 2015.
OXIS Biotech Retains The Emmes Group To Assist With Its Strategic Business And Therapeutic Development Initiatives
PR Newswire - Tue May 12, 6:30AM CDT
Oxis Biotech, Inc. (OXIS), a wholly owned subsidiary of Oxis International, Inc. [OTC: OXIS] announced today that it has retained the Emmes Group to assist with the development and execution of the Company's business, partnership, and technology licensing initiatives and strategies.
How High Have Cannabis Stocks Been This Year And Where Do You Stand?
ACCESSWIRE - Fri May 08, 11:10AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 8, 2015 / Interest in cannabis companies has continued to grow in 2015 as more states have begun to implement legalization efforts; these including options for both medical and recreational use. After more states like Texas have put wheels in motion for legalization efforts, more attention has begun to build and the 2015 market for cannabis stocks has started to look much different than the uncertainty that was seen last year. Companies like Oxis International (OTCQB: OXIS), Pazoo, Inc. (PINKSHEETS: PZOO), and Totally Hemp Crazy Inc (PINKSHEETS: THCZ) have all seen record 6-month highs this year as a flood of positive news and a more informed investment community have bolstered movement within the market.
The "Tech" Behind Biotechnology Has Evolved; 2015 Marks New Milestones
ACCESSWIRE - Thu May 07, 10:01AM CDT
CORAL GABLES, FL / ACCESSWIRE / May 7, 2015 / The biotechnology industry has come a long way from where it was even 10 years ago. New findings, developments, and enacted regulations have given rise to programs only once dreamed of. Nearly half of America is behind the legalization of cannabis; many in favor of medical use and other novel therapies to treat the effects of cancer. Companies like Oxis International, Inc. (OTCQB: OXIS), PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), and PharmaCyte Biotech, Inc. (OTCQB: PMCB) have all begun the push for brining certain therapies to market.
PTBI: 6.61 (+0.08)
Will These Cannabis Stocks Be On Your Watchlist For May?
ACCESSWIRE - Tue May 05, 1:14PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 5, 2015 / Marijuana stocks have made a serious comeback since the start of the New Year. With the hit taken by cannabis companies in 2014 it has attracted investors to invest in oversold cannabis plays. Now it's 2015 and with 23 states including the District of Columbia jumping on the marijuana legislation train, companies are finding new innovative ways to become part of the cannabis industry. For example, biotech/cannabis focused companies like Oxis International (OTCQB: OXIS), Hemp infused beverage wholesalers like Totally Hemp Crazy Inc. (PINKSHEETS: THCZ) and even extensive security & protection services like Blue Line Protection Group (PINKSHEETS: BLPG) have all found their niche in the industry.
Reviews Of 15 Marijuana Stocks Before The Marijuana Investor Summit - Part VIII
Anthony Cataldo - at Seeking Alpha - Mon Apr 20, 7:25AM CDT
QAI: 29.10 (+0.04)
